

Murray Baron

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2603001/publications.pdf>

Version: 2024-02-01

177
papers

7,991
citations

41258

49
h-index

60497

81
g-index

177
all docs

177
docs citations

177
times ranked

7116
citing authors

#	ARTICLE	IF	CITATIONS
1	Damage Trajectories in Systemic Sclerosis Using Group-Based Trajectory Modeling. <i>Arthritis Care and Research</i> , 2023, 75, 640-647.	1.5	5
2	Immunosuppression use in early systemic sclerosis may be increasing over time. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 33-41.	1.0	4
3	Oxidative stress-induced senescence mediates inflammatory and fibrotic phenotypes in fibroblasts from systemic sclerosis patients. <i>Rheumatology</i> , 2022, 61, 1265-1275.	0.9	19
4	NT-proBNP, hs-cTnT, and CRP predict the risk of cardiopulmonary outcomes in systemic sclerosis: Findings from the Canadian Scleroderma Research Group. <i>Journal of Scleroderma and Related Disorders</i> , 2022, 7, 62-70.	1.0	6
5	Association between autoantibodies in systemic sclerosis and cancer in a national registry. <i>Rheumatology</i> , 2022, 61, 2905-2914.	0.9	11
6	Geographical distribution of systemic sclerosis in Canada: An ecologic study based on the Canadian Scleroderma Research Group. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 1095-1097.	0.6	2
7	Associations between the Composite Response Index in Diffuse Cutaneous Systemic Sclerosis (CRISS), survival and other disease measures. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 53, 151973.	1.6	4
8	Change in calcinosis over 1 year using the scleroderma clinical trials consortium radiologic scoring system for calcinosis of the hands in patients with systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2022, 53, 151980.	1.6	10
9	Screening and management of subclinical interstitial lung disease in systemic sclerosis: an international survey. <i>Rheumatology</i> , 2022, 61, 3401-3407.	0.9	3
10	Health Care Utilization Is Increased In Systemic Sclerosis Patients Who Have Digital Ulcers. <i>Arthritis Care and Research</i> , 2022, , .	1.5	1
11	Toward Understanding of Environmental Risk Factors in Systemic Sclerosis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2021, 25, 188-204.	0.6	17
12	Association of Autologous Hematopoietic Stem Cell Transplantation in Systemic Sclerosis With Marked Improvement in Health-Related Quality of Life. <i>Arthritis and Rheumatology</i> , 2021, 73, 305-314.	2.9	10
13	Trigeminal neuralgia in systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 318-323.	1.6	0
14	Systematic Analysis of the Literature in Search of Defining Systemic Sclerosis Subsets. <i>Journal of Rheumatology</i> , 2021, 48, jrheum.201594.	1.0	6
15	Association Between Immunosuppressive Therapy and Incident Risk of Interstitial Lung Disease in Systemic Sclerosis. <i>Chest</i> , 2021, 160, 2158-2162.	0.4	5
16	Association between gastroprotective agents and risk of incident interstitial lung disease in systemic sclerosis. <i>Respiratory Medicine</i> , 2021, 185, 106482.	1.3	1
17	Sudden Cardiac Death in Systemic Sclerosis: Diagnostics to Assess Risk and Inform Management. <i>Diagnostics</i> , 2021, 11, 1781.	1.3	4
18	Immunosuppression does not prevent severe gastrointestinal tract involvement in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 142-148.	0.4	0

#	ARTICLE	IF	CITATIONS
19	A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. <i>Clinical and Experimental Rheumatology</i> , 2021, 39 Suppl 131, 124-133.	0.4	1
20	A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 124-133.	0.4	11
21	Immunosuppression does not prevent severe gastrointestinal tract involvement in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 142-148.	0.4	6
22	Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis. <i>Rheumatology</i> , 2020, 59, 1108-1117.	0.9	12
23	The Accuracy of the Patient Health Questionnaire-9 Algorithm for Screening to Detect Major Depression: An Individual Participant Data Meta-Analysis. <i>Psychotherapy and Psychosomatics</i> , 2020, 89, 25-37.	4.0	67
24	Changes in skin score in early diffuse cutaneous systemic sclerosis are associated with changes in global disease severity. <i>Rheumatology</i> , 2020, 59, 398-406.	0.9	19
25	Can Patient-reported Symptoms Be Used to Measure Disease Activity in Systemic Sclerosis?. <i>Arthritis Care and Research</i> , 2020, 72, 1459-1465.	1.5	12
26	Equivalency of the diagnostic accuracy of the PHQ-8 and PHQ-9: a systematic review and individual participant data meta-analysis. <i>Psychological Medicine</i> , 2020, 50, 1368-1380.	2.7	175
27	Small intestinal bacterial overgrowth in systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 33-39.	1.0	4
28	Mammalian target of rapamycin is activated in the kidneys of patients with scleroderma renal crisis. <i>Journal of Scleroderma and Related Disorders</i> , 2020, 5, 152-158.	1.0	2
29	Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2020, 59, 1715-1724.	0.9	14
30	Calcinosis is associated with ischemic manifestations and increased disability in patients with systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 891-896.	1.6	26
31	Immunosuppressive treatment in diffuse cutaneous systemic sclerosis is associated with an improved composite response index (CRISS). <i>Arthritis Research and Therapy</i> , 2020, 22, 132.	1.6	5
32	Comment on: Skin improvement is a surrogate for favourable changes in other organ systems in early diffuse cutaneous systemic sclerosis: reply. <i>Rheumatology</i> , 2020, 59, 1783-1784.	0.9	1
33	Protocol for a partially nested randomised controlled trial to evaluate the effectiveness of the scleroderma patient-centered intervention network COVID-19 home-isolation activities together (SPIN-CHAT) program to reduce anxiety among at-risk scleroderma patients. <i>Journal of Psychosomatic Research</i> , 2020, 135, 110132.	1.2	21
34	FRI0258...CUMULATIVE INCIDENCE, SURVIVAL AND PREDICTORS OF PULMONARY HYPERTENSION IN SYSTEMIC SCLEROSIS SUBSETS: PAH IS NOT INCREASED IN LIMITED VS DIFFUSE PATIENTS BY ADJUSTED COMPETING RISK ANALYSIS. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 713-713.	0.5	33
35	Defining primary systemic sclerosis heart involvement: A scoping literature review. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 874-887.	1.6	35
36	Methods for shortening patient-reported outcome measures. <i>Statistical Methods in Medical Research</i> , 2019, 28, 2992-3011.	0.7	25

#	ARTICLE	IF	CITATIONS
37	An interim report of the Scleroderma Clinical Trials Consortium working groups. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 17-27.	1.0	13
38	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. <i>Rheumatology</i> , 2019, , .	0.9	0
39	Development and validation of the Scleroderma Clinical Trials Consortium Damage Index (SCTC-DI): a novel instrument to quantify organ damage in systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 807-816.	0.5	33
40	Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. <i>Arthritis and Rheumatology</i> , 2019, 71, 964-971.	2.9	41
41	Severe gastrointestinal disease in very early systemic sclerosis is associated with early mortality. <i>Rheumatology</i> , 2019, 58, 636-644.	0.9	34
42	Bicaudal D2 is a novel autoantibody target in systemic sclerosis that shares a key epitope with CENP-A but has a distinct clinical phenotype. <i>Autoimmunity Reviews</i> , 2018, 17, 267-275.	2.5	19
43	Reliability and Validity of Three Versions of the Brief Fear of Negative Evaluation Scale in Patients With Systemic Sclerosis: A Scleroderma Patient-centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2018, 70, 1646-1652.	1.5	8
44	Probability of major depression diagnostic classification using semi-structured versus fully structured diagnostic interviews. <i>British Journal of Psychiatry</i> , 2018, 212, 377-385.	1.7	53
45	Patient acceptable symptom state in scleroderma: results from the tocilizumab compared with placebo trial in active diffuse cutaneous systemic sclerosis. <i>Rheumatology</i> , 2018, 57, 152-157.	0.9	13
46	Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate). <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 212-220.	0.5	236
47	Interstitial lung disease is associated with an increased risk of lung cancer in systemic sclerosis: Longitudinal data from the Canadian Scleroderma Research Group. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 221-227.	1.0	8
48	The challenges and controversies of measuring disease activity in systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2018, 3, 115-121.	1.0	10
49	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. <i>Rheumatology</i> , 2018, 57, 1623-1631.	0.9	53
50	Determinants of health-related quality of life in a multinational systemic sclerosis inception cohort. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 53-60.	0.4	6
51	Validation of the Body Concealment Scale for Scleroderma (BCSS): Replication in the Scleroderma Patient-centered Intervention Network (SPIN) Cohort. <i>Body Image</i> , 2017, 20, 99-106.	1.9	3
52	The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 270-276.	0.5	132
53	Performance of the Patient-Reported Outcomes Measurement Information System-29 in scleroderma: a Scleroderma Patient-centered Intervention Network Cohort Study. <i>Rheumatology</i> , 2017, 56, 1302-1311.	0.9	51
54	Antifibrillar Antibodies Are Associated with Native North American Ethnicity and Poorer Survival in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2017, 44, 799-805.	1.0	25

#	ARTICLE	IF	CITATIONS
55	Predictive value of European Scleroderma Group Activity Index in an early scleroderma cohort. <i>Rheumatology</i> , 2017, 56, 1111-1122.	0.9	11
56	Transethnic meta-analysis identifies <i>GSDMA</i> and <i>PRDM1</i> as susceptibility genes to systemic sclerosis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1150-1158.	0.5	77
57	Early Mortality in a Multinational Systemic Sclerosis Inception Cohort. <i>Arthritis and Rheumatology</i> , 2017, 69, 1067-1077.	2.9	139
58	The association of sociodemographic and objectively-assessed disease variables with fatigue in systemic sclerosis: an analysis of 785 Canadian Scleroderma Research Group Registry patients. <i>Clinical Rheumatology</i> , 2017, 36, 373-379.	1.0	9
59	ADAM10-mediated ephrin-B2 shedding promotes myofibroblast activation and organ fibrosis. <i>Nature Medicine</i> , 2017, 23, 1405-1415.	15.2	99
60	Assessment of English-French differential item functioning of the Satisfaction with Appearance Scale (SWAP) in systemic sclerosis. <i>Body Image</i> , 2017, 22, 97-102.	1.9	5
61	Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	155
62	The Comparability of Functional Assessment of Chronic Illness Therapy - Fatigue Scores between Cancer and Systemic Sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 57-63.	1.0	2
63	Digital Ulcers in Ssc Treated with Oral Treprostinil: A Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Follow-up. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 42-49.	1.0	25
64	Defining Skin Ulcers in Systemic Sclerosis: Systematic Literature Review and Proposed World Scleroderma Foundation (WSF) Definition. <i>Journal of Scleroderma and Related Disorders</i> , 2017, 2, 115-120.	1.0	62
65	Relationship between calcium channel blockers and skin fibrosis in patients with systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2017, 35 Suppl 106, 56-60.	0.4	2
66	Subsets in systemic sclerosis: one size does not fit all. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 298-306.	1.0	11
67	Validation of the Self-Efficacy for Managing Chronic Disease Scale: A Scleroderma Patient-Centered Intervention Network Cohort Study. <i>Arthritis Care and Research</i> , 2016, 68, 1195-1200.	1.5	31
68	Late Nailfold Videocapillaroscopy Pattern Associated With Hand Calcinosis and Acro-Osteolysis in Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2016, 68, 366-373.	1.5	40
69	Clinical correlates of faecal incontinence in systemic sclerosis: identifying therapeutic avenues. <i>Rheumatology</i> , 2016, 56, kew441.	0.9	13
70	Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial. <i>Lancet, The</i> , 2016, 387, 2630-2640.	6.3	505
71	Calcinosis is associated with digital ischaemia in systemic sclerosis—a longitudinal study. <i>Rheumatology</i> , 2016, 55, 2148-2155.	0.9	52
72	Summed and Weighted Summary Scores for the Medsger Disease Severity Scale Compared with the Physician's Global Assessment of Disease Severity in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2016, 43, 1510-1518.	1.0	12

#	ARTICLE	IF	CITATIONS
73	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2016, 68, 167-178.	1.5	13
74	Relationship Between Disease Characteristics and Oral Radiologic Findings in Systemic Sclerosis: Results From a Canadian Oral Health Study. <i>Arthritis Care and Research</i> , 2016, 68, 673-680.	1.5	24
75	Development and Validation of the Body Concealment Scale for Scleroderma. <i>Arthritis Care and Research</i> , 2016, 68, 1158-1165.	1.5	11
76	Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 344-349.	1.6	66
77	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. <i>Arthritis Research and Therapy</i> , 2016, 18, 20.	1.6	18
78	The American College of Rheumatology Provisional Composite Response Index for Clinical Trials in Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2016, 68, 299-311.	2.9	110
79	The Impact of Pain and Itch on Functioning and Health-Related Quality of Life in Systemic Sclerosis: An Exploratory Study. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 43-53.	0.6	32
80	Anti-HMGR antibodies in systemic sclerosis. <i>Medicine (United States)</i> , 2016, 95, e5280.	0.4	4
81	Targeted Therapy in Systemic Sclerosis. <i>Rambam Maimonides Medical Journal</i> , 2016, 7, e0030.	0.4	11
82	Reasons for non-participation in scleroderma support groups. <i>Clinical and Experimental Rheumatology</i> , 2016, 34 Suppl 100, 56-62.	0.4	12
83	Novel Approaches to Discovery of Biomarkers in Rheumatoid Arthritis: Comment on the Article by Oswald et al. <i>Arthritis and Rheumatology</i> , 2015, 67, 2276-2277.	2.9	2
84	Relationship Between Disease Characteristics and Orofacial Manifestations in Systemic Sclerosis: Canadian Systemic Sclerosis Oral Health Study III. <i>Arthritis Care and Research</i> , 2015, 67, 681-690.	1.5	42
85	Systemic Sclerosis. <i>Rheumatic Disease Clinics of North America</i> , 2015, 41, 459-473.	0.8	78
86	Specificity of Systemic Sclerosis Classification Criteria. <i>Journal of Rheumatology</i> , 2015, 42, 2512-2512.	1.0	3
87	The Canadian Systemic Sclerosis Oral Health Study II: the relationship between oral and global health-related quality of life in systemic sclerosis. <i>Rheumatology</i> , 2015, 54, 692-696.	0.9	20
88	The Canadian Systemic Sclerosis Oral Health Study IV: oral radiographic manifestations in systemic sclerosis compared with the general population. <i>Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology</i> , 2015, 120, 104-111.	0.2	40
89	Can the Cancer-related Fatigue Case-definition Criteria Be Applied to Chronic Medical Illness? A Comparison between Breast Cancer and Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2015, 42, 1156-1162.	1.0	5
90	Antinuclear antibody-negative systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 680-686.	1.6	60

#	ARTICLE	IF	CITATIONS
91	Thinking outside the box—The associations with cutaneous involvement and autoantibody status in systemic sclerosis are not always what we expect. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 184-189.	1.6	29
92	Clinical correlates of monospecific anti-PM75 and anti-PM100 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects. <i>Autoimmunity</i> , 2015, 48, 542-551.	1.2	29
93	2013 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Systemic Sclerosis Outperform the 1980 Criteria: Data From the Canadian Scleroderma Research Group. <i>Arthritis Care and Research</i> , 2015, 67, 582-587.	1.5	60
94	Monospecific anti-Ro52/TRIM21 antibodies in a tri-nation cohort of 1574 systemic sclerosis subjects: evidence of an association with interstitial lung disease and worse survival. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S131-5.	0.4	24
95	The Comparability of English, French and Dutch Scores on the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F): An Assessment of Differential Item Functioning in Patients with Systemic Sclerosis. <i>PLoS ONE</i> , 2014, 9, e91979.	1.1	13
96	Systemic Sclerosis Immunoglobulin Induces Growth and a Pro-Fibrotic State in Vascular Smooth Muscle Cells through the Epidermal Growth Factor Receptor. <i>PLoS ONE</i> , 2014, 9, e100035.	1.1	15
97	Absence of an association between anti-Ro antibodies and prolonged QTc interval in systemic sclerosis: A multicenter study of 689 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 338-344.	1.6	28
98	Reply. <i>Arthritis Care and Research</i> , 2014, 66, 497-498.	1.5	0
99	The Canadian systemic sclerosis oral health study: orofacial manifestations and oral health-related quality of life in systemic sclerosis compared with the general population. <i>Rheumatology</i> , 2014, 53, 1386-1394.	0.9	65
100	Cells from the skin of patients with systemic sclerosis secrete chitinase 3-like protein 1. <i>BBA Clinical</i> , 2014, 1, 2-11.	4.1	11
101	Consensus opinion of a North American Working Group regarding the classification of digital ulcers in systemic sclerosis. <i>Clinical Rheumatology</i> , 2014, 33, 207-214.	1.0	48
102	Systemic Sclerosis Sine Scleroderma: A Multicenter Study of 1417 Subjects. <i>Journal of Rheumatology</i> , 2014, 41, 2179-2185.	1.0	63
103	Effect of menopause on the modified Rodnan skin score in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2014, 16, R130.	1.6	38
104	Autoantibodies to the Rpp25 Component of the Th/To Complex are the Most Common Antibodies in Patients with Systemic Sclerosis without Antibodies Detectable by Widely Available Commercial Tests. <i>Journal of Rheumatology</i> , 2014, 41, 1334-1343.	1.0	22
105	ImmunoChip Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. <i>American Journal of Human Genetics</i> , 2014, 94, 47-61.	2.6	182
106	Clinical and Serologic Correlates of Anti-PM/Scl Antibodies in Systemic Sclerosis: A Multicenter Study of 763 Patients. <i>Arthritis and Rheumatology</i> , 2014, 66, 1608-1615.	2.9	90
107	Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis—Results from the International Scleroderma Renal Crisis Survey. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 666-672.	1.6	115
108	Multicriteria decision analysis methods with 1000Minds for developing systemic sclerosis classification criteria. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 706-714.	2.4	52

#	ARTICLE	IF	CITATIONS
109	An Assessment of the Measurement Equivalence of English and French Versions of the Center for Epidemiologic Studies Depression (CES-D) Scale in Systemic Sclerosis. <i>PLoS ONE</i> , 2014, 9, e102897.	1.1	9
110	Prevalence and clinical correlates of pruritus in patients with systemic sclerosis: an updated analysis of 959 patients. <i>Rheumatology</i> , 2013, 52, 2056-2061.	0.9	43
111	The 15% Rule in Scleroderma: The Frequency of Severe Organ Complications in Systemic Sclerosis. A Systematic Review. <i>Journal of Rheumatology</i> , 2013, 40, 1545-1556.	1.0	127
112	Does cigarette smoking mitigate the severity of skin disease in systemic sclerosis?. <i>Rheumatology International</i> , 2013, 33, 943-948.	1.5	13
113	Comparison of different measures of diffusing capacity for carbon monoxide (DLCO) in systemic sclerosis. <i>Clinical Rheumatology</i> , 2013, 32, 1467-1474.	1.0	7
114	The Scleroderma Patient-centered Intervention Network (SPIN) Cohort: protocol for a cohort multiple randomised controlled trial (cmRCT) design to support trials of psychosocial and rehabilitation interventions in a rare disease context. <i>BMJ Open</i> , 2013, 3, e003563.	0.8	104
115	Low Socioeconomic Status (Measured by Education) and Outcomes in Systemic Sclerosis: Data from the Canadian Scleroderma Research Group. <i>Journal of Rheumatology</i> , 2013, 40, 447-454.	1.0	15
116	Systemic Sclerosis in Canada's North American Native Population: Assessment of Clinical and Serological Manifestations. <i>Journal of Rheumatology</i> , 2013, 40, 1121-1126.	1.0	14
117	Prevalence of current, 12-month and lifetime major depressive disorder among patients with systemic sclerosis. <i>Rheumatology</i> , 2013, 52, 669-675.	0.9	31
118	Utility of the Patient Health Questionnaire-9 to Assess Suicide Risk in Patients With Systemic Sclerosis. <i>Arthritis Care and Research</i> , 2013, 65, 753-758.	1.5	34
119	Sleep disturbances in systemic sclerosis: evidence for the role of gastrointestinal symptoms, pain and pruritus. <i>Rheumatology</i> , 2013, 52, 1715-1720.	0.9	39
120	Association of Gastroesophageal Factors and Worsening of Forced Vital Capacity in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2013, 40, 850-858.	1.0	52
121	Associations with Organ Involvement and Autoantibodies in Systemic Sclerosis: Results from the Canadian Scleroderma Research Group (CSRG). <i>Open Journal of Rheumatology and Autoimmune Diseases</i> , 2013, 03, 113-118.	0.1	11
122	Focal adhesion kinase and reactive oxygen species contribute to the persistent fibrotic phenotype of lesional scleroderma fibroblasts. <i>Rheumatology</i> , 2012, 51, 2146-2154.	0.9	51
123	Patient-reported outcome measures in systemic sclerosis: Comment on the article by Hinchcliff et al. <i>Arthritis Care and Research</i> , 2012, 64, 942-943.	1.5	0
124	Immunosuppression for interstitial lung disease in systemic sclerosis – novel insights and opportunities for translational research. <i>Journal of Cell Communication and Signaling</i> , 2012, 6, 187-190.	1.8	4
125	Clinical significance of antibodies to Ro52/TRIM21 in systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2012, 14, R50.	1.6	110
126	Sociodemographic and Disease Correlates of Body Image Distress among Patients with Systemic Sclerosis. <i>PLoS ONE</i> , 2012, 7, e33281.	1.1	44

#	ARTICLE	IF	CITATIONS
127	Clinical decision rule to predict the presence of interstitial lung disease in systemic sclerosis. <i>Arthritis Care and Research</i> , 2012, 64, 519-524.	1.5	117
128	Rates and correlates of sexual activity and impairment among women with systemic sclerosis. <i>Arthritis Care and Research</i> , 2012, 64, 340-350.	1.5	23
129	Sexual Activity and Impairment in Women with Systemic Sclerosis Compared to Women from a General Population Sample. <i>PLoS ONE</i> , 2012, 7, e52129.	1.1	17
130	New directions for patient-centred care in scleroderma: the Scleroderma Patient-centred Intervention Network (SPIN). <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S23-9.	0.4	28
131	Associations with digital ulcers in a large cohort of systemic sclerosis: Results from the Canadian Scleroderma Research Group registry. <i>Arthritis Care and Research</i> , 2011, 63, 142-149.	1.5	118
132	Modeling smoking in systemic sclerosis: A comparison of different statistical approaches. <i>Arthritis Care and Research</i> , 2011, 63, 570-578.	1.5	12
133	Cigarette smoking in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2011, 63, 230-238.	6.7	74
134	Measuring Pain in Systemic Sclerosis: Comparison of the Short-form McGill Pain Questionnaire Versus a Single-item Measure of Pain. <i>Journal of Rheumatology</i> , 2011, 38, 2581-2587.	1.0	14
135	Registries in systemic sclerosis: a worldwide experience. <i>Rheumatology</i> , 2011, 50, 60-68.	0.9	45
136	Frequency and impact of symptoms experienced by patients with systemic sclerosis: results from a Canadian National Survey. <i>Rheumatology</i> , 2011, 50, 762-767.	0.9	188
137	Clinical correlates of sleep problems in systemic sclerosis: the prominent role of pain. <i>Rheumatology</i> , 2011, 50, 921-925.	0.9	23
138	Validation of the UCLA Scleroderma Clinical Trial Gastrointestinal Tract Instrument Version 2.0 for Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2011, 38, 1925-1930.	1.0	29
139	Prevalence, severity, and clinical correlates of pain in patients with systemic sclerosis. <i>Arthritis Care and Research</i> , 2010, 62, 409-417.	1.5	69
140	Psychological health and well-being in systemic sclerosis: State of the science and consensus research agenda. <i>Arthritis Care and Research</i> , 2010, 62, 1181-1189.	1.5	79
141	Association of pruritus with quality of life and disability in systemic sclerosis. <i>Arthritis Care and Research</i> , 2010, 62, 1489-1495.	1.5	43
142	Development and validation of the brief satisfaction with appearance scale for systemic sclerosis. <i>Arthritis Care and Research</i> , 2010, 62, 1779-1786.	1.5	35
143	Discordance between Patient and Physician Assessments of Disease Severity in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2010, 37, 2307-2312.	1.0	32
144	Comparison of the PHQ-9 and CES-D depression scales in systemic sclerosis: internal consistency reliability, convergent validity and clinical correlates. <i>Rheumatology</i> , 2010, 49, 789-796.	0.9	118

#	ARTICLE	IF	CITATIONS
145	Is Serum Albumin a Marker of Malnutrition in Chronic Disease? The Scleroderma Paradigm. <i>Journal of the American College of Nutrition</i> , 2010, 29, 144-151.	1.1	28
146	Screening and therapy for malnutrition and related gastro-intestinal disorders in systemic sclerosis: recommendations of a North American expert panel. <i>Clinical and Experimental Rheumatology</i> , 2010, 28, S42-6.	0.4	23
147	The cost of systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2009, 61, 119-123.	6.7	62
148	Evaluation of the clinimetric properties of the Early Inflammatory Arthritis-self-administered comorbidity questionnaire. <i>Rheumatology</i> , 2009, 48, 390-394.	0.9	10
149	Clinical Correlates of Self-reported Physical Health Status in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2009, 36, 1226-1229.	1.0	16
150	Quality of Life in Patients with Systemic Sclerosis Compared to the General Population and Patients with Other Chronic Conditions. <i>Journal of Rheumatology</i> , 2009, 36, 768-772.	1.0	64
151	Malnutrition Is Common in Systemic Sclerosis: Results from the Canadian Scleroderma Research Group Database. <i>Journal of Rheumatology</i> , 2009, 36, 2737-2743.	1.0	114
152	Work Disability in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2009, 36, 2481-2486.	1.0	61
153	Time to diagnosis in systemic sclerosis: Is sex a factor?. <i>Arthritis and Rheumatism</i> , 2009, 61, 274-278.	6.7	35
154	Sociodemographic, disease, and symptom correlates of fatigue in systemic sclerosis: Evidence from a sample of 659 Canadian Scleroderma Research Group Registry patients. <i>Arthritis and Rheumatism</i> , 2009, 61, 966-973.	6.7	59
155	Health-related quality of life in systemic sclerosis: A systematic review. <i>Arthritis and Rheumatism</i> , 2009, 61, 1112-1120.	6.7	129
156	Prevalence and clinical correlates of pruritus in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2009, 61, 1765-1770.	6.7	31
157	Reliability and validity of the center for epidemiologic studies depression scale in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2008, 59, 438-443.	6.7	77
158	Quality of life in systemic sclerosis: Psychometric properties of the World Health Organization Disability Assessment Schedule II. <i>Arthritis and Rheumatism</i> , 2008, 59, 270-278.	6.7	68
159	Clinical correlates of quality of life in systemic sclerosis measured with the World Health Organization Disability Assessment Schedule II. <i>Arthritis and Rheumatism</i> , 2008, 59, 279-284.	6.7	47
160	Prevalence and clinical correlates of symptoms of depression in patients with systemic sclerosis. <i>Arthritis and Rheumatism</i> , 2008, 59, 504-509.	6.7	86
161	Development of the McGill Range of Motion Index. <i>Clinical Orthopaedics and Related Research</i> , 2007, 456, 42-50.	0.7	4
162	Depression in patients with systemic sclerosis: A systematic review of the evidence. <i>Arthritis and Rheumatism</i> , 2007, 57, 1089-1097.	6.7	131

#	ARTICLE	IF	CITATIONS
163	Office capillaroscopy in systemic sclerosis. <i>Clinical Rheumatology</i> , 2007, 26, 1268-1274.	1.0	62
164	The development of systemic sclerosis classification criteria. <i>Clinical Rheumatology</i> , 2007, 26, 1401-1409.	1.0	48
165	Outcome measurements in scleroderma: results from a delphi exercise. <i>Journal of Rheumatology</i> , 2007, 34, 501-9.	1.0	45
166	Hepatic Overlap Syndrome Improved With Infliximab. <i>Gastroenterology and Hepatology</i> , 2006, 2, 88-90.	0.2	1
167	Prevalence of elevated pulmonary arterial pressures measured by echocardiography in a multicenter study of patients with systemic sclerosis. <i>Journal of Rheumatology</i> , 2005, 32, 1273-8.	1.0	60
168	A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. <i>Arthritis and Rheumatism</i> , 2001, 44, 1351-1358.	6.7	361
169	A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma. , 2001, 44, 1351.		1
170	The needs of patients with arthritis: The patient's perspective. <i>Arthritis and Rheumatism</i> , 1999, 12, 85-95.	6.7	67
171	Comparison of Amitriptyline, Cyclobenzaprine, and Placebo in the Treatment of Fibromyalgia. <i>Arthritis and Rheumatism</i> , 1994, 37, 32-40.	6.7	325
172	Inflammation and cartilage metabolism in rheumatoid arthritis. <i>Studies of the Blood Markers Hyaluronic Acid, Orosomucoid, and Keratan Sulfate</i> . <i>Arthritis and Rheumatism</i> , 1990, 33, 790-799.	6.7	91
173	Colonic telangiectasias in a patient with progressive systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1986, 29, 282-285.	6.7	16
174	Aseptic necrosis of the talus and calcaneal insufficiency fractures in a patient with pancreatitis, subcutaneous fat necrosis, and arthritis. <i>Arthritis and Rheumatism</i> , 1984, 27, 1309-1313.	6.7	38
175	⁶⁷ Gallium lung scans in progressive systemic sclerosis. <i>Arthritis and Rheumatism</i> , 1983, 26, 969-974.	6.7	28
176	Pancreatitis in systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 1982, 25, 1006-1009.	6.7	31
177	Effect of pregnancy on scleroderma progression. <i>Journal of Scleroderma and Related Disorders</i> , 0, , 239719832211013.	1.0	0